Metabolon, Inc., a Research Triangle Park, N.C. – based global leader in metabolomics, raised $15m in funding.
Essex Woodlands, a healthcare growth equity firm, made the investment. Metabolon and Essex Woodlands have the ability to increase the purchase up to an additional $10m, proceeds of which would be utilized to repurchase shares from existing investors. As part of the financing, Scott Barry, Managing Director at Essex Woodlands, will join Metabolon’s board of directors.
The company, which has raised approximately $80m in funding to date, will use the proceeds to further develop and commercialize its pipeline of precision medicine products employing its proprietary metabolomics technology.
Founded in 2000 and led by John Ryals, Ph.D., president and CEO, Metabolon is a health technology company focused on the use of metabolomics in precision medicine. Its tool for assessing health – based on proprietary platforms and informatics – delivers biomarker discoveries, innovative diagnostic tests, and partnerships in genomics-based health initiatives. The company’s expertise is also accelerating research and product development across the pharmaceutical, biotechnology, consumer products, agriculture and nutrition industries, as well as academic and government organizations.
To date, Metabolon has conducted more than 5,000 independent and collaborative studies, resulting in over 600 peer-reviewed publications.